Study of ABSK211 for advanced solid tumors with KRAS changes
Part of Cancer clinical trials.
This trial tests a new drug called ABSK211 in people with advanced solid tumors that have a change in the KRAS gene. The goal is to see if the drug is safe and works against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- Your cancer must have spread or cannot be removed by surgery and has a KRAS change.
- You must be able to take care of yourself (ECOG score 0 or 1).
- You must have adequate organ and bone marrow function.
- You must not have had certain prior treatments targeting KRAS or RAS.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called ABSK141 for people with advanced solid tumors that have a specific mutation called KRAS G12D. It aims to see if the drug can shrink or control the cancer, and it has different phases for different groups of patients.
This trial tests a new drug called ABSK131 in people whose cancer has a missing MTAP gene. It is for advanced solid tumors that have not responded to standard treatments.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a new vaccine, ABO2102, for people with advanced solid tumors that have a specific change in the KRAS gene. The vaccine aims to help your immune system fight the cancer.
This early-phase trial is testing a new mRNA vaccine (ABO2102) designed to target KRAS mutations in advanced solid tumors. It may be an option if your cancer has a KRAS mutation and standard treatments are no longer working.
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
Hear when a new Solid Tumor (Phase I) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.